Regular exercise and sufficient protein intake can help maintain muscle and preserve long-term health in patients taking ...
November's wave of FDA oncology approvals signals the industry's shift toward platform-based precision therapies over broad-spectrum approaches([1]) . The global anticancer drug market now values ...
November's wave of FDA oncology approvals signals the industry's shift toward platform-based precision therapies over broad-spectrum approaches([1]) . The global anticancer drug market now values ...
Glioblastoma is the most common form of brain cancer in adults, and its consequences are usually quick and fatal. After ...
The total pancreatic cancer market size is expected to increase in the 7MM during the forecast period, driven by ongoing ...
Glioblastoma is the most common form of brain cancer in adults, and its consequences are usually quick and fatal. After ...
Placebo-adjusted mean weight loss of 11.3% (27.3 lbs) with 120 mg dose in the 36-week Phase 2b ACCESS study with a 10.4% adverse event-related ...
When cells can’t destroy damaged proteins, a hidden backup system led by NRF1 steps in to prevent toxic buildup.
All G is gearing up to launch its first product—recombinant bovine lactoferrin—in Q1 2026, says CEO Jan Pacas.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback